A novel model to study mechanisms of cholestasis in human cholangiocytes reveals a role for the SIPR2 pathway.

Authors:
Islam D; Israr I; Taleb MAB; Rao A; Yosief R and 7 more

Journal:
Hepatol Commun

Publication Year: 2024

DOI:
10.1097/HC9.0000000000000389

PMCID:
PMC10898671

PMID:
38407207

Journal Information

Full Title: Hepatol Commun

Abbreviation: Hepatol Commun

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology & Hepatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICTS OF INTEREST Binita M. Kamath: Mirum (Consultant and Unrestricted educational grant), Albireo (Consultant and Unrestricted educational grant), Audentes (Consultant). Saul J. Karpen: Consultant for Albireo, Mirum, HemoShear, and Intercept. Michael Trauner: research grants from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda, and Ultragenyx and travel grants from Abbvie, Falk, Gilead Intercept, and Jannsen. He further has advised for Abbvie, Albireo, BiomX, Boehringer Ingelheim, Falk Pharma GmbH, Genfit, Gilead, Hightide, Intercept, Janssen, MSD, Novartis, Phenex, Pliant, Regulus, Siemens, and Shire and has served as speaker for Albireo, BMS, Falk, Gilead, Intercept, Madrigal, and MSD. He is a coinventor of patents for the medical use of norUDCA (norursodeoxycholic acid/norucholic acid) filed by the Medical Universities of Graz and Vienna. The remaining authors have no conflicts to report."

Evidence found in paper:

"FUNDING INFORMATION This study was supported by CIHR project grant #175211."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025